培美曲塞与吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的对比研究
Comparisive study between pemetrexed and gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer
-
摘要: 目的：探讨培美曲塞与吉西他滨联合顺铂一线治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法：分析晚期NSCLC一线化疗病人46例，采用培美曲塞联合顺铂化疗组22例（培美曲塞组），吉西他滨联合顺铂化疗组24例（吉西他滨组）。比较2组病人的近期疗效、中位无疾病进展生存时间（PFS）和不良反应发生情况。结果：培美曲塞组和吉西他滨组的客观缓解率分别为36.4%和29.2%，疾病控制率分别为62.5%和45.8%，中位PFS分别为6.5个月和6.0个月，差异均无统计学意义（P>0.05）。2组病人不良反应均可耐受。培美曲塞组和吉西他滨组粒细胞减少分别为36.4%（8/22）和66.7%（16/24），差异有统计学意义（P<0.05）。结论：培美曲塞或吉西他滨联合顺铂治疗晚期NSCLC的临床疗效相似，但前者不良反应发生率减低，病人耐受性较好，值得临床推广。Abstract: Objective:To explore the clinical efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:Among 46 patients with advanced NSCLC,22 cases were treated with pemetrexed combined with cisplatin(pemetrexed group) and 24 cases were treated with gemcitabine combined with cisplatin(gemcitabine group).The short-term efficacy,median disease-free progression survival(PFS) time and adverse reactions between two groups were compared.Results:The objective remission rate,disease control rate and median PFS in pemetrexed group and gemcitabine group were(36.4% and 29.2%),(62.5% and 45.8%),and(6.5 and 6.0 months),respectively,and the differences of the objective remission rate,disease control rate and median PFS between two groups were not statistically significant(P>0.05).The adverse reactions in two groups were tolerable.The rates of neutrophil reduction in pemetrexed group and gemcitabine group were 36.4%(8/22) and 66.7%(16/24),respectively,and the difference of which between two groups was statistically significant(P<0.05).Conclusions:The clinical effect between pemetrexed combined with cisplatin and gemcitabine combined with cisplatin in the treatment of advanced NSCLC is similar,but the pemetrexed combined with cisplatin is less toxicities,good tolerability,worthy of application.
-
Key words:
- non-small-cell lung cancer /
- pemetrexed /
- gemcitabine
-
[1] SIEGEL RL,MILLER KD,JEMAL A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67(1):7. [2] CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115. [3] HASSAN LA,HASSAN O,YANG YW,et al.Lung cancer:biology and treatment options[J].Biochim Biophys Acta,2015,1856(2):189. [4] MASTERS GA,TEMIN S,AZZOLI CG,et al.Systemic therapy for stage IV non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2015,33(30):3488. [5] SCAGLIOTTI GV,PARIKH P,VON PAWEL J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543. [6] 胡兴胜,焦顺昌,张树才,等.培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究[J].中国肺癌杂志,2012,15(10):569. [7] 母丹,叶璐,付波.培美曲塞或紫杉醇联合顺铂治疗晚期非鳞非小细胞肺癌的临床观察[J].武警后勤学院学报(医学版),2017,26(6):493. [8] 王丽,史美祺,夏国豪,等.培美曲塞联合顺铂或卡铂一线治疗ⅢB/Ⅳ期非小细胞肺癌临床观察[J].南京医科大学学报(自然科学版),2012,32(2):241. [9] ZHENG Z,LI X,SCHELL MJ,et al.Thymidylate synthase in situ protein expression and survival in stage I non-smallcell lung cancer[J].Cancer,2008,112(12):2765. [10] 范洪峰,芮晓艳,张艳喜,等.TS和RRM1表达与培美曲塞、吉西他滨联合卡铂治疗晚期非鳞非小细胞肺癌疗效的关系[J].实用癌症杂志,2017,32(5):776. [11] KALIKAKI A,KOUTSOPOULOS A,HATZIDAKI D,et al.Clinical out come of patients with nonsmall cell lung cancer receiving front line chemotherapy according to EGFR and K-RAS mutation status[J].Lung Cancer,2010,69(1):110. [12] 李俊,徐同鹏,郭人花,等.EGFR基因突变状态与晚期肺腺癌一线化疗疗效的相关性[J].实用药物与临床,2017,20(8):883. [13] PARK S,KEAM B,KIM SH,et al.Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations[J].Cancer Res Treat,2015,47(4):630. [14] LIANG Y,WAKELEE HA,NEAL JW.Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer[J].Clin Lung Cancer,2015,16(5):366. [15] 杨新杰,张卉,张权,等.培美曲塞或吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的临床随机对照研究[J].中华肿瘤防治杂志,2012,19(6):453. -
点击查看大图
计量
- 文章访问数: 3765
- HTML全文浏览量: 579
- PDF下载量: 21
- 被引次数: 0
下载:
